References
- Chang M, Dahl ML, Tybring G, et al. (1995). Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358–63.
- Danielson PB. (2002). The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561–97.
- Fan L, Wang G, Wang LS, et al. (2007). Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacologica Sinica 28:1685.
- Gonzalez HM, Romero EM, Peregrina AA, et al. (2003). CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 43:1211–5.
- Jiang S, Meadows J, Anderson SA, Mukkada AJ. (2002). Antileishmanial activity of the antiulcer agent omeprazole. Antimicrob. Agents Chemother 46:2569–74.
- Kandel SE, Lampe JN. (2014). Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity. Chem Res Toxicol 27:1474–86.
- Kiljander TO, Salomaa ERM, Hietanen EK, Terho EO. (2000). Chronic cough and gastro‐oesophageal reflux: a double‐blind placebo‐controlled study with omeprazole. Eur Respir J 16:633–8.
- Kinoshita N, Yamaguchi Y, Hou XL, et al. (2011). Experimental adjustment on drug interactions through intestinal CYP3A activity in rat: impacts of kampo medicines repeat administered. Evidence-Based Complementray Altern Med 2011:827435.
- Krau SD. (2013). Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems. Nurs Clin North Am 48:681–96.
- Li FY, Hao HP, Hao K, et al. (2013). Effect of diammonium glycyrrhizinate on entecavir pharmacokinetics in rats. Chin J Nat Med 11:309–13.
- Li P, Zou H, Ren Y, et al. (2014). Antiviral effect of diammonium glycyrrhizinate on cell infection by porcine parvovirus. Curr Microbiol 69:82–7.
- Long L, Huang C. (2014). Therapeutic effect of flupentixol and melitracen combined with omeprazole and mosapride citrate in treatment of functional dyspepsia. Med Innov China 90:93–7.
- Ma CY, Yang SY, Zhang H, et al. (2008). Prediction models of human plasma protein binding rate and oral bioavailability derived by using GA–CG–SVM method. J Pharm Biomed Anal 47:677–82.
- Mizunashi K, Furukawa Y, Katano K, Abe K. (1993). Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–5.
- Pergolizzi JV, Labhsetwar SA, Puenpatom RA, et al. (2011). Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Practice 11:230–9.
- Seven M, Batar B, Unal S, et al. (2014). The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children. Mol Diagn Ther 18:229–36.
- Sridhar J, Liu J, Foroozesh M, Stevens CLK. (2012). Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies. Molecules 17:9283.
- Sugimoto M, Furuta T. (2012). Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol 5:49–59.
- Tari A, Kuruhara Y, Yonei Y, et al. (2001). Effects of omeprazole and pirenzepine on enterochromaffin-like cells and parietal cells in rat stomach. J. Gastroenterol 36:375–85.
- Termanini B, Gibril F, Stewart CA, et al. (1996). A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 10:61–71.
- Watanabe K, Furuno K, Eto K, et al. (1994). First-pass metabolism of omeprazole in rats. J Pharm Sci 83:1131–4.
- Wedemeyer RS, Blume H. (2014). Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 37:201–11.
- Welage LS, Berardi RR. (2000). Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 40:52–62.
- Tolou-Ghamari Z. (2012). Antiepileptic drugs (AEDs) polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett 6:207–12.
- Yang J, Peng RX, Kong R, Yu JP. (2001). Effects OF 18α-glycyrrhizic acid on rat liver cytochrome p450 isoenzymes and phase II transferase. Acta Pharmaceutica Sinica 36:321–4.